Diligence memo · auto-generated · as of July 2, 2026
Biolog, Inc. /DE/
Biolog, Inc. /DE/ looks fair against its niche peers and is active on financing cadence.
Businessfiled
Biolog, Inc. /DE/ operates in Biotechnology, based in HAYWARD.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Biolog, Inc. /DE/ has raised $34M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $18M on 2022-04-28.
Most recent recorded round closed around 2025-02-10.
Valuation (modeled)modeled
Provath models Biolog, Inc. /DE/ at approximately $88M (range $32M–$141M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.14× the median modeled value of Series B Biotechnology companies in 2025–2027 (94 peers) — value vs value, same stage and era. Within the normal band (114% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 17 months.
Last raise 17 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 76% of Biotechnology peers (4293 compared).
Modeled value ranks above 56% of those peers.
Closest niche peers: MarvelBiome, Inc., Iantrek, Inc., Dualitas Therapeutics, Inc., Antares Therapeutics, Inc., OrthoBio Therapeutics, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.